Consolidated Statements Of Cash Flows (Parenthetical) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2014
Additional cash flow information
Impairment expense, restructuring and lease termination costs	[1]	$ 2,054	$ 0
Impairment of long-lived assets to be disposed of		7,440
Gain (Loss) on Contract Termination		5,300
Deferred Finance Costs, Gross			8,200
Debt Instrument, Unamortized Discount		6,564	8,783
Principal		886,283	956,250
Payments of Financing Costs	[2]	9	2,911
Repurchases of common stock	[3]	$ (159,800)	(545,091)
Credit Facility
Additional cash flow information
Deferred Finance Costs, Gross			2,200
Senior Unsecured Notes due 2021 | Senior Notes
Additional cash flow information
Debt Instrument, Unamortized Discount				$ 4,500
Principal			300,000
Senior Unsecured Notes due 2019 | Senior Notes
Additional cash flow information
Deferred Finance Costs, Gross			1,500
Tender Offer
Additional cash flow information
Professional fees paid			3,700
Payments for Fees			$ 3,700

[1] The non-cash restructuring, impairment and related costs in 2015 of $2.1 million is composed of $7.4 million in impairments of lease related assets partially offset by a $5.3 million benefit resulting from the lease termination. The 2013 non-cash charge represents asset impairments of $32.7 million related to our four ventures previously included in our former New Ventures segment, Orango, Rubi, Crisp Market, and Star Studio, which were discontinued during 2013.

[2] Total financing costs associated with the Credit Facility and senior unsecured notes issued in 2014 were $8.2 million composed of non-cash debt issue costs of $4.5 million recorded as debt discount associated with our issuance of $300.0 million senior unsecured notes due 2021, $1.5 million in deferred financing fees associated with the senior unsecured notes, and $2.2 million in deferred financing fees associated with the refinancing of our Credit Facility. The cash payments for financing costs associated with the Credit Facility and senior unsecured notes in 2014 were $2.9 million.

[3] The total cost of repurchases of common stock in 2014 was $545.1 million, which includes $3.7 million in fees and expenses relating to the tender offer recorded as part of the cost of treasury stock in our Consolidated Balance Sheets. The cash payments for the tender offer fees in 2014 were $3.7 million.